Sign In
20 Apr 2017 11:20
20 April 2017
REDX PHARMA PLC
("Redx" or "the Company")
Result of Annual General Meeting
Redx, the drug discovery and development company, announces that all resolutions at the Group's Annual General Meeting, held today, were duly passed.
For further information, please contact:
Redx Pharma Plc | |
Neil Murray, Chief Executive | T: +44 1625 469 900 |
Karl Hård, Head of Investor Relations & Corporate Communications | T: +44 7491 651 406 |
Cantor Fitzgerald Europe (Nomad & Joint Broker) |
T: +44 20 7894 7000 |
Phil Davies / Michael Reynolds |
About Redx Pharma Plc
Company website: redxpharma.com
Redx is focused on the discovery and development of proprietary, small molecule therapeutics to address areas of high, unmet medical need, principally in cancer, infection and immunology, providing a pipeline of assets to larger and emerging companies. By improving the characteristics of existing drug classes to create highly differentiated, novel, best-in-class drugs, Redx has already established a broad portfolio of proprietary drug programs.
Follow the stocks
